ReviewEuropean journal of medical research2026
Neuroinflammation and blood-brain barrier dysfunction in cerebral small vessel disease: mechanisms, biomarkers, and therapeutic implications.
Review in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Small-Molecule NANT Therapeutics Targeting the Brain-Immune Axis in Alzheimer's Disease: Mechanisms, Clinical Progress, and Translational Challenges.Molecules (Basel, Switzerland) · 2026Review
- PVT inhibition mitigates neuropathology and cognitive deficits in chronic cerebral hypoperfusion.iScience · 2026Article
- Interleukin-6 is associated with white matter hyperintensities and cognition independent of Alzheimer's disease plasma biomarkers-HABS-HD.Journal of Alzheimer's disease : JAD · 2026Article
- Review
- In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia-Telangiectasia.Chemical biology & drug design · 2026Article
- Roles of Microglia in Cerebral Small Vessel Disease.CNS neuroscience & therapeutics · 2026Review
- Friend or foe? Glial-vascular interactions in health and neurodegenerative disease.Pharmacological reviews · 2026Review
- Hyperlipidemia induces hippocampal inflammation and loss of vascularity and can be rescued by silencing RIPK1.Scientific reports · 2026Article
- New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Tissue-specific diffusion abnormalities and localized free-water reductions in hypertension despite no detectable group difference in the DTI-ALPS index.Frontiers in medicine · 2026Article
- The unified cardiometabolic disease continuum: mechanistic stages of a single pathophysiological process.Frontiers in endocrinology · 2026Review
- Systemic inflammation and cerebrovascular injury in acute stroke.Revista da Associacao Medica Brasileira (1992) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral small vessel disease (CSVD) is a chronic, progressive cerebrovascular disorder affecting small arteries, arterioles, venules, and capillaries, and is a leading contributor to stroke, vascular dementia, and cognitive impairment. Accumulating evidence has revealed that the pathogenesis of CSVD is multifactorial, with neuroinflammation and blood-brain barrier (BBB) dysfunction emerging as central pathological processes. Notably, a bidirectional feedback loop between neuroinflammation and BBB breakdown has been identified. Endothelial cells, microglia, oligodendrocytes, as main cell components in maintaining the physiological functions of BBB performed significant roles. Imaging modalities have improved detection of BBB permeability changes and CSVD progression. Recent translational research has identified potential biomarkers for early diagnosis. Therefore, some new therapeutic approaches targeting the neuroinflammation-BBB axis can provide better early intervention for CSVD and have superior therapeutic effects. In our review, we first elaborated on the pathological role of CSVD, particularly emphasizing the importance of the integrity of the BBB. Then, we highlighted the clinical characteristics and translational research evidence of CSVD, including novel imaging and biochemical biomarkers, potential therapeutic approaches, and the progress of preclinical models, thereby revealing the research progress of CSVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.